<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03970616</url>
  </required_header>
  <id_info>
    <org_study_id>AV-951-18-121</org_study_id>
    <nct_id>NCT03970616</nct_id>
  </id_info>
  <brief_title>A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma</brief_title>
  <acronym>DEDUCTIVE</acronym>
  <official_title>A Phase 1b/2, Open-Label, Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AVEO Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AVEO Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, DLTs, MTD, and preliminary anti tumor&#xD;
      activity of tivozanib in combination with durvalumab in subjects with advanced HCC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Phase 1 followed by expansion cohort</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Approximately 24 months; Through study completion</time_frame>
    <description>To establish the safety of tivozanib in combination with durvalumab in subjects with untreated advanced hepatocellular carcinoma (HCC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Approximately 24 months; Through study completion</time_frame>
    <description>To establish the safety of tivozanib in combination with durvalumab in subjects with advanced hepatocellular carcinoma (HCC) previously treated with both bevacizumab and atezolizumab.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate (Objective Response Rate)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>To estimate the response rate of tivozanib in combination with durvalumab in subjects with untreated advanced HCC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>To estimate the progression free survival (PFS) of tivozanib in combination with durvalumab in subjects with untreated advanced HCC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Approximately 24 months; Through study completion</time_frame>
    <description>To estimate the overall survival (OS) of tivozanib in combination with durvalumab in subjects with untreated advanced HCC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate (Objective Response Rate)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>To estimate the response rate of tivozanib in combination with durvalumab in subjects with advanced HCC previously treated with both bevacizumab and atezolizumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Approximately 24 months; Through study completion</time_frame>
    <description>To estimate the progression free survival (PFS) of tivozanib in combination with durvalumab in subjects with advanced HCC previously treated with both bevacizumab and atezolizumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Approximately 24 months; Through study completion</time_frame>
    <description>To estimate the overall survival (OS) of tivozanib in combination with durvalumab in subjects with advanced HCC previously treated with both bevacizumab and atezolizumab.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Tivozanib in Combination with Durvalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tivozanib in Combination with Durvalumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tivozanib</intervention_name>
    <description>Dose level 1: 1.0mg for 21 days followed by 7 days rest; Dose level -1: 1.0mg every other day</description>
    <arm_group_label>Tivozanib in Combination with Durvalumab</arm_group_label>
    <other_name>Fotivda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>1500mg every 28 days</description>
    <arm_group_label>Tivozanib in Combination with Durvalumab</arm_group_label>
    <other_name>Imfinzi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥ 18 years old&#xD;
&#xD;
          2. Signed and dated written informed consent&#xD;
&#xD;
          3. Histologically or cytologically confirmed unresectable locally advanced or metastatic&#xD;
             hepatocellular carcinoma. Measurable or evaluable disease by RECIST 1.1 criteria.&#xD;
             Patients can be either untreated or have progressed on both bevacizumab and&#xD;
             atezolizumab.&#xD;
&#xD;
          4. Child-Pugh Class A.&#xD;
&#xD;
          5. ECOG performance status ≤ 1 (see Appendix A) and life expectancy ≥ 3 months.&#xD;
&#xD;
          6. Body weight &gt; 30 kg.&#xD;
&#xD;
          7. Measured creatinine clearance (crCL) &gt;40 mL/min or calculated crCL &gt;40 mL/min as&#xD;
             determined by Cockcroft-Gault (using actual body weight).&#xD;
&#xD;
          8. Sexually active pre-menopausal female subjects (and female partners of male subjects)&#xD;
             must use highly effective contraceptive measures, while on study and for at least 90&#xD;
             days after the last dose of study drug. Sexually active male subjects must use&#xD;
             adequate contraceptive measures, while on study and for at least 90 days after the&#xD;
             last dose of study drug. All fertile male and female subjects and their partners must&#xD;
             agree to use a highly effective method of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have received prior systemic treatment for HCC except for both&#xD;
             bevacizumab and atezolizumab.&#xD;
&#xD;
          2. Female subjects who are pregnant or breastfeeding or male or female subjects of&#xD;
             reproductive potential who are not willing to employ effective birth control from&#xD;
             screening to 90 days after the last dose of study drug.&#xD;
&#xD;
          3. Brain metastases or spinal cord compression. Subjects with suspected brain metastases&#xD;
             at screening should have an MRI (preferred) or CT scan each preferable with IV&#xD;
             contrast of the brain prior to study entry. Brain metastases will not be recorded on&#xD;
             RECIST Target Lesions at baseline.&#xD;
&#xD;
          4. Any of the following hematologic abnormalities:&#xD;
&#xD;
               -  Hemoglobin &lt; 9.0 g/dL&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt; 1500 per mm3&#xD;
&#xD;
               -  Platelet count &lt; 75,000 per mm3&#xD;
&#xD;
          5. Any of the following serum chemistry or urinalysis abnormalities:&#xD;
&#xD;
               -  Total bilirubin &gt; 2 × ULN (&gt;2.5 mg/dL in subjects with Gilbert's syndrome)&#xD;
&#xD;
               -  AST or ALT &gt; 5 × ULN&#xD;
&#xD;
               -  Alkaline phosphatase &gt; 2.5 × ULN (or &gt; 5 × ULN for subjects with liver or bone&#xD;
                  metastasis)&#xD;
&#xD;
               -  Serum creatinine &gt; 1.5 × ULN •&gt; 2+ proteinuria&#xD;
&#xD;
          6. History of hepatic encephalopathy within past 12 months or requirement for medications&#xD;
             to prevent or control encephalopathy (eg, no lactulose, rifaximin, etc if used for&#xD;
             purposes of hepatic encephalopathy).&#xD;
&#xD;
          7. GI Bleeding (eg, esophageal varices or ulcer bleeding) within 12 months. (Note: For&#xD;
             patients with a history of GI bleeding for more than 12 months or assessed as high&#xD;
             risk for esophageal variceal bleed by the Investigator, adequate endoscopic therapy&#xD;
             according to institutional standards is required).&#xD;
&#xD;
          8. Clinically meaningful ascites defined as ascites requiring non-pharmacologic&#xD;
             intervention (eg, paracentesis) to maintain symptomatic control, within 6 months prior&#xD;
             to the first scheduled dose. Subjects on stable doses of diuretics for ascites for ≥ 2&#xD;
             months are eligible.&#xD;
&#xD;
          9. Main portal vein thrombosis (Vp4) as documented on imaging. (VP4 is defined as portal&#xD;
             vein thrombosis in the main trunk of the portal vein or a portal vein branch&#xD;
             contralateral to the primarily involved lobe (or both).&#xD;
&#xD;
         10. For subjects who require ongoing therapeutic anti-coagulation or anti-platelet&#xD;
             therapy; the subject must be off either therapy for at least 7 days prior to the first&#xD;
             dose of investigational product. Low-dose aspirin for cardiac prophylaxis/protection&#xD;
             is permitted per local institutional standards.&#xD;
&#xD;
         11. Patients co-infected with HBV and HCVHBV positive [presence of hepatitis B surface&#xD;
             antigen (HBsAg) and/or hepatitis B core antibodies (anti-HBcAb) with detectable HBV&#xD;
             DNA (≥10IU/ml)]; HCV positive (presence of anti-HCV antibodies).&#xD;
&#xD;
         12. Major surgery (as defined by the investigator) within 28 days prior to first dose of&#xD;
             IP or still recovering from prior surgery. Local procedures (eg, core needle biopsy,&#xD;
             and prostate biopsy) are allowed if completed at least 3 days prior to the&#xD;
             administration of the first dose of study treatment.&#xD;
&#xD;
         13. Significant cardiovascular disease, including:&#xD;
&#xD;
               -  Clinically symptomatic heart failure. Subjects with a history of heart failure&#xD;
                  must have an ECHO or MUGA scan to document left ventricular ejection fraction&#xD;
                  (LVEF) &gt; 45% prior to start of protocol therapy&#xD;
&#xD;
               -  Any New York Heart Association classification ≥ Class 2 (prefer Class 0 or 1)&#xD;
&#xD;
               -  Any stenting procedure within the last 3 months&#xD;
&#xD;
               -  Venous thromboembolism or arterial thromboembolism within the last 3 months&#xD;
&#xD;
               -  Any IVC tumor thrombosis&#xD;
&#xD;
               -  History of a hemorrhagic event (i.e., GI bleed within 6 months)&#xD;
&#xD;
               -  Uncontrolled hypertension: blood pressure &gt;150/95 mmHg on more than 2&#xD;
                  antihypertensive medications, on two consecutive measurements obtained at least&#xD;
                  24 hours apart. Subjects with a history of hypertension must have been on stable&#xD;
                  doses of anti-hypertensive drugs for ≥ 2 weeks prior to start of protocol&#xD;
                  therapy.&#xD;
&#xD;
               -  Myocardial infarction within 3 months prior to start of protocol therapy&#xD;
&#xD;
         14. Subjects with delayed healing of wounds, ulcers, and/or bone fractures&#xD;
&#xD;
         15. Serious/active infection or infection requiring parenteral antibiotics&#xD;
&#xD;
         16. Inadequate recovery from any prior surgical procedure; major surgical procedure within&#xD;
             4 weeks prior to start of protocol therapy.&#xD;
&#xD;
         17. Inability to comply with protocol requirements&#xD;
&#xD;
         18. History of another primary malignancy except for:&#xD;
&#xD;
               -  Malignancy treated with curative intent and with no known active disease ≥ 5&#xD;
                  years before the first dose of study drug and low potential risk for recurrence&#xD;
&#xD;
               -  Adequately treated non-melanoma skin cancer of lentigo maligna without evidence&#xD;
                  of disease&#xD;
&#xD;
         19. Active infection including tuberculosis (clinical evaluation that includes clinical&#xD;
             history, physical examination and radiographic findings, and tuberculosis testing in&#xD;
             line with local practice), hepatitis C, or human immunodeficiency virus (positive HIV&#xD;
             1/2 antibodies). Subjects positive for hepatitis C (HCV) antibody are eligible only if&#xD;
             polymerase chain reaction is negative for HCV RNA.&#xD;
&#xD;
         20. Patients with a history or current HBV infection (detectable HBV DNA), should be&#xD;
             placed on anti-viral treatment and tested at every cycle for HBV DNA viral load.&#xD;
&#xD;
         21. Palliative radiotherapy with a limited field of radiation within 2 weeks or with wide&#xD;
             field of radiation or to more than 30% of the bone marrow within 4 weeks before the&#xD;
             first dose of study intervention.&#xD;
&#xD;
         22. Treatment with systemic hormonal therapy within 3 weeks prior to start of protocol&#xD;
             therapy, with the exception of:&#xD;
&#xD;
               -  Hormonal therapy for appetite stimulation or contraception&#xD;
&#xD;
               -  Nasal, ophthalmic, inhaled and topical steroid preparations&#xD;
&#xD;
               -  Oral replacement therapy for adrenal insufficiency&#xD;
&#xD;
               -  Low-dose maintenance steroid therapy (equivalent of prednisone 10mg/day) for&#xD;
                  other conditions&#xD;
&#xD;
               -  Hormone replacement therapy such as testosterone&#xD;
&#xD;
         23. Strong CYP3A4 inducers (see Appendix B) within 2 weeks prior to start of, or during,&#xD;
             protocol therapy.&#xD;
&#xD;
         24. Prior exposure to tivozanib or durvalumab. For subjects who have received prior&#xD;
             atezolizumab:&#xD;
&#xD;
               -  Must not have experienced a toxicity that led to permanent discontinuation of&#xD;
                  prior immunotherapy.&#xD;
&#xD;
               -  All AEs while receiving prior immunotherapy must have completely resolved or&#xD;
                  resolved to baseline prior to screening for this study.&#xD;
&#xD;
               -  Must not have experienced a Grade ≥ 3 immune-related AE or an immune-related&#xD;
                  neurologic or ocular AE of any grade while receiving prior immunotherapy. Note:&#xD;
                  Participants with an endocrine AE of Grade ≤ 2 are permitted to enroll if they&#xD;
                  are stably maintained on appropriate replacement therapy and are asymptomatic.&#xD;
&#xD;
               -  Must not have required the use of additional immunosuppression other than&#xD;
                  corticosteroids for the management of an AE, not have experienced recurrence of&#xD;
                  an AE if re-challenged, and not currently require maintenance doses of &gt; 10 mg&#xD;
                  prednisone or equivalent per day.&#xD;
&#xD;
         25. History of allogeneic organ transplantation&#xD;
&#xD;
         26. Active or prior documented autoimmune or inflammatory disorders (including&#xD;
             inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with&#xD;
             the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome,&#xD;
             or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid&#xD;
             arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this&#xD;
             criterion:&#xD;
&#xD;
               -  Subjects with vitiligo or alopecia&#xD;
&#xD;
               -  Subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable on&#xD;
                  hormone replacement&#xD;
&#xD;
               -  Any chronic skin condition that does not require systemic therapy&#xD;
&#xD;
               -  Subjects without active disease in the last 5 years may be included but only&#xD;
                  after consultation with Medical Monitor&#xD;
&#xD;
               -  Subjects with celiac disease controlled by diet alone&#xD;
&#xD;
         27. Uncontrolled intercurrent illness, including but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable&#xD;
             angina pectoris, uncontrolled cardiac arrhythmia, active interstitial lung disease,&#xD;
             serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric&#xD;
             illness/social situations that would limit compliance with study requirement,&#xD;
             substantially increase risk of incurring AEs or compromise the ability of the subject&#xD;
             to give written informed consent&#xD;
&#xD;
         28. History of leptomeningeal carcinomatosis&#xD;
&#xD;
         29. History of active primary immunodeficiency&#xD;
&#xD;
         30. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms&#xD;
             calculated from 3 ECGs (within 15 minutes at 5 minutes apart)&#xD;
&#xD;
         31. Known allergy or hypersensitivity to any of the study drugs or any of the study drug&#xD;
             excipients&#xD;
&#xD;
         32. Concurrent enrollment in another clinical study, unless it is an observational (non&#xD;
             interventional) clinical study or during the follow-up period of an interventional&#xD;
             study&#xD;
&#xD;
         33. Receipt of live attenuated vaccine within 30 days prior to the first dose of study&#xD;
             drug. Note: Subjects, if enrolled, should not receive live vaccine whilst receiving&#xD;
             study drug and up to 30 days after the last dose of study drug.&#xD;
&#xD;
         34. Current or prior use of immunosuppressive medication within 14 days before the first&#xD;
             dose of durvalumab. The following are exceptions to this criterion:&#xD;
&#xD;
               -  Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra&#xD;
                  articular injection)&#xD;
&#xD;
               -  Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of&#xD;
                  prednisone or its equivalent&#xD;
&#xD;
               -  Steroids as premedication for hypersensitivity reactions (e.g., CT scan&#xD;
                  premedication)&#xD;
&#xD;
         35. Previous study drug assignment in the present study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chief Medical Officer</last_name>
    <phone>857-400-0101</phone>
    <email>Clinical@aveooncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California - Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarcoma Oncology Research Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston (UTHealth)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Tyler (UTHealth)</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 28, 2019</study_first_submitted>
  <study_first_submitted_qc>May 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2019</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

